Picture of doctor speaking to patient

SHINGRIX: Recommendations from NACI and CIQ

NACI Recommendation

Checkmark icon Checkmark icon

The National Advisory Committee on Immunization (NACI) recommends that SHINGRIX should be offered to adults 50 years of age and older (strong recommendation).1

According to NACI, a strong recommendation applies to most individuals and should be followed unless a clear and compelling rationale for an alternative approach is present.1

Refer to the NACI statement on the Public Health Agency website for further information.

© All rights reserved. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccine. Public Health Agency of Canada modified: 2018. Adapted and reproduced with permission from the Minister of Health, 2018.

CIQ Recommendation

Checkmark icon Checkmark icon

The Comité sur l’immunisation du Québec (CIQ) preferentially recommends SHINGRIX for adults 50 years of age and older.2

References

  1. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.
  2. Reproduction of information from the PIQ, 7th ed. Zona-SU section. Available at: http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/.
    The original French version of this information was published in 2018 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.
  3. SHINGRIX Product Monograph. GlaxoSmithKline Inc., June 3, 2020.

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK Group of Companies or its licensor.

PM-CA-SGX-WCNT-210001 | November 2021